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In the late 19th century, early 20th, the main known rheumatic diseases were Gout, deforming
arthritis (osteoarthritis), acute rheumatism (rheumatic fever), and chronic rheumatism [rheumatoid
arthritis (RA)]. There was uncertainty whether acute and chronic rheumatisms were separate
diseases or a single entity with heterogeneous manifestations according to the influence of age,
heredity, and environment. At the turn of the last century, the possibility of a bacterial etiology of
both diseases began to be considered (1). In this scenario, the demonstration of circulating factors
interacting with self-structures, later recognized as autoantibodies, contributed substantially to the
establishment of the concept of autoimmunity and autoimmune diseases.
One of the earliest observations of the agglutinating capacity of rheumatoid sera was that of R.
Cecil et al. at Cornell University, in 1930 (1). They found that such sera agglutinated suspensions
of streptococci. H. Dawson at Columbia University, in 1932, showed that agglutination was also
seen when pneumococci’s suspensions were used. These systems of agglutination were studied as
diagnostic tests, but gave positive results in <50% of cases of RA (1). In 1937, while monitoring the
results of Wassermann’s serology at Oslo City Hospital, Erick Waaler observed an unusual result,
with agglutination rather than hemolysis of the red cells (the agglutinating activating factor) (2).
In 1939, at the Third International Congress for Microbiology, in New York, Waaler presented the
results on 77 RA patients, 27 of whom presented a positive test for the agglutination of erythrocytes.
In 1948, using a complement fixation test for Rickettsia, the same phenomenon of sensitized
sheep red cells agglutination with rheumatoid sera was seen and reported by H. Rose et al. at the
Presbyterian Hospital (1).
The agglutinating factor was tentatively termed “rheumatoid factor (RF)” by Coggeshall et al. (3)
and its identification as an antibody to antigens in the Fc region of immunoglobulin G has led to
immunological studies that allowed us a better understanding of the etiopathogenesis of RA (4).
The use of latex particles instead of the sheep red cells led to a more sensitive, though less specific,
assay that soon gained wide clinical acceptance (5). Automated techniques such as nephelometry
and immunoturbidimetric assays gradually replaced the other semiquantitative methods because of
their greater sensitivity and reproducibility, as well as adaptability to automation (6).
The introduction of enzyme-linked immunosorbent assays (ELISA) allowed a better characteriza-
tion of the different isotypes of RF but their utility in clinical practice has never gained popularity. In
fact, more or less at the same time precursors of what would be the anti-citrullinated peptide/protein
antibody system (ACPA) were identified as a major antigenic target of RA-specific autoantibodies.
In 1964, Nienhuis and Mandema reported a novel autoantibody system designated antiperin-
uclear factor (APF). They showed that sera from RA patients reacted in a very specific way with
keratohyalin granules present in buccal mucosa cells. Fifteen years later, also using sera from
patients with RA in an indirect immunofluorescence (IFI) assay, Young et al. described the so-
called “antikeratin” antibodies (AKA) on cryosections of rat esophagus. It took many years and a
lot of work done by independent groups of researchers led by Hoet, Sene, Sebbag, Schellekens, and
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Girbauld-Neuhauser until the target of both the APF and AKA
was recognized as the same antigenic protein: citrullinated
(pro)filaggrin.
Despite been highly specific for RA, the difficulties in availabil-
ity, standardization, and interpretation of the indirect IFI method
for APF and AKA hindered the widespread popularization of
these tests. The situation was drastically changed with the devel-
opment of ELISA-based tests with pools of selected citrullinated
peptides. Careful selection of cyclic citrullinated peptides, chosen
from peptide libraries according to the ability to discriminate
RA sera, was used to increase the sensitivity and specificity of
the test (6, 7). Progressively, other antigenic substrates, such as
citrullinated vimentin, were also shown to be useful for the clinical
detection of ACPA.
Studies on the diagnostic performance of ACPA demonstrated
that they are highly specific for RA and appear several years before
disease onset (7). However, they are not essential for development
of the RA syndrome, as a sizable number of patients (around
30–40%) do not produce them. The argument that ACPA-positive
RA could be a distinct disease than ACPA-negative RA has been
put forward based on clinical, epidemiological and genetic obser-
vations (7).
In terms of clinical observations, ACPA positivity has been
associated with a more destructive disease course, as well as with
cardiovascular complications, while ACPA negativity has been
associated with drug-free remission (7).
Most interestingly, epidemiological studies demonstrated that
smoking is a risk factor only for ACPA-positive RA. In addition,
the RA-associated shared epitope containing alleles of the HLA-
DRB1 gene are strongly associated with the development of ACPA
(8). Indeed, there is a strong interaction between these two risk
factors, smoking andHLA-DRB1 gene, demonstrating for the first
time in RA a clear gene–environment interaction effect. These
observations led to the proposal of a pathogenetic model in which
smoke exposure induces citrullination in the lung, and HLA-
DRB1 shared epitope-restricted immune reactions to these pep-
tides trigger systemic inflammation and, eventually, a local second
hit induces chronic synovial disease. More recently, additional
associations have been reported involving shared epitope HLA-
DRB1 alleles, PTPN22 (another gene associated with RA) and
smoking with the presence of specific ACPA reactivities, mainly
against citrullinated α-enolase and vimentin (9).
Still in terms of genetic background, genome-wide association
studies (GWAS) comparing ACPA-positive and ACPA-negative
disease have shown that these two subsets of patients present
different risk allele frequencies that were mainly confined to the
HLA region, providing further support for distinct genetic eti-
ologies (10). A more refined GWAS with ACPA-negative patients
confirmed the HLA and several suggestive non-HLA regions of
association, with a dense analysis focused on the HLA region
identifying a two amino acid model (HLA-B at position 9 and
HLA-DRB1 at position 11, both mapping to the peptide-binding
groove of the receptor). For example, the presence of a serine
at position 11 of the HLA-DRB1 would confer susceptibility to
ACPA-negative, but protection to ACPA-positive disease, whereas
the presence of aspartic acid or valine was a risk factor for ACPA-
positive and mildly protective of ACPA-negative disease (11).
The two autoantibody systems, ACPA and RF, described for
RA, have had their clinical relevance extensively investigated in
the last few years. Both have traditionally been associated with
more severe disease and bone damage. In fact, a mechanism for
bone damage in ACPA patients has been proposed, involving
the induction and differentiation of bone resorbing osteoclasts
by antibodies against citrullinated vimentin (12). In this study,
ACPA titers in RA patients were correlated with serum mark-
ers for osteoclast-mediated bone resorption. The authors also
identified that antibodies against mutated citrullinated vimentin
bound to osteoclast surfaces and induced osteoclastogenesis and
bone-resorption activity, with evidence that this effect was medi-
ated by local release of TNF from osteoclast precursors. On the
other hand, the role of RF on bone damage, independent of the
presence of ACPA, is less well defined, although mechanisms
involving Fc cross-linking on macrophage surface leading to pro-
osteoclastogenic cytokine release have been suggested.
Some recent studies have tried to determine whether patients
with isolated RF or ACPA also constitute different subsets of the
disease and whether double positivity confers additional risk fac-
tor for destructive disease. Exploring potential genetic differences
of these putative RA subsets, C. Terao et al. performed genotyping
of the HLA-DRB1 allele in 954 ACPA-negative Japanese patients
that were negative or positive for the RF, and compared with
ACPA-positive patients (13). Their conclusion was that, in fact,
ACPA-negative RA includes two genetically distinctive subsets
according to the presence of RF: ACPA-negative/RF-positive RA
is associated with HLA-DRB1*04:05 and *09:01, whereas ACPA-
negative/RF-negative RA was associated with DR14 and HLA-
DR8 homozygote.
In another study, J. Sokolove et al. sought to investigate the
role of RF as a contributor to the RA inflammatory burden in
isolation or in synergy with ACPA (14). For that, they analyzed
disease activity and serum levels of cytokines and multiple ACPA
specificities in a cohort of 1,488 US veterans with RA, comparing
the different groups of patients: double-negative, single-positive
(ACPA or RF), and double-positive patients. They observed that
the double-positive subgroup indeed had higher disease activ-
ity and higher levels of inflammatory cytokines as compared to
double-negative or single-positive subgroups. In support to that,
in vitro studies demonstrated that the presence of IgM-RF could
significantly increase the production of tumor necrosis factor by
macrophages stimulated with ACPA immune complexes (14).
Finally C. Hecht et al., from Erlangen, studied the effect of
ACPA and RF on the number and size of bone erosion by high-
resolution peripheral quantitative CT scans of the metacarpo-
phanlangeal joints in 238 RA patients (112 double-positive, 28
RF-positive, 29 ACPA-positive, 69 double-negative) (15). They
observed that double-positive patients had the highest number
and size of erosions, with significant difference in the erosion
number as compared to double-negative patients and in erosion
size as compared to ACPA-negative patients. A linear regression
mixed model showed that ACPA-positive/RF-positive status and
disease duration was associated with higher number and larger
size of bone erosions. In addition, the effect of RF on erosions was
observed only in ACPA-positive patients. Therefore, the authors
concluded that there is an interdependence of ACPA and RF in
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RA-mediated bone damage, being the RF a strong enhancer of the
ACPA effect on the bone, and emphasizing the pathogenic role of
both autoantibodies (15).
In conclusion, RF and ACPA are present in a substantial
majority of RA patients, but a sizable fraction of patients is
double-negative. Recent clinical and genetic studies have strongly
indicated that in fact the presence of ACPA can be a marker
of different subsets of RA, presenting with distinct risk factors,
prognosis, and response to treatment. Additionally, the con-
comitant presence of both autoantibodies seems to be associated
with higher disease activity and increased risk of bone damage.
ACPA and RF have been included in the new 2010 ACR/EULAR
Rheumatoid Arthritis Classification Criteria, demonstrating their
strong discriminative diagnostic performance. With the recent
data presented, it is becoming more evident that testing for these
antibodies could also add important information for the therapeu-
tic planning of these patients.
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